Role of ARNi in Ventricular Remodeling in Hypertensive LVH

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Hypertensive Heart Disease
Interventions
DRUG

Entresto

Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.

DRUG

Valsartan

Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.

Trial Locations (1)

169609

National Heart Centre Singapore, Singapore

All Listed Sponsors
collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

National Heart Centre Singapore

OTHER

NCT03553810 - Role of ARNi in Ventricular Remodeling in Hypertensive LVH | Biotech Hunter | Biotech Hunter